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Abstract
Background: Gestational hypertension (GH) and pre-eclampsia (PE) can result in severe complications such as
eclampsia, placental abruption, syndrome of Hemolysis, Elevated Liver enzymes and Low Platelets (HELLP) and
ultimately even neonatal or maternal death. We recently showed that in women with GH or mild PE at term
induction of labour reduces both high risk situations for mothers as well as the caesarean section rate. In view of
this knowledge, one can raise the question whether women with severe hypertension, pre-eclampsia or
deterioration chronic hypertension between 34 and 37 weeks of gestation should be delivered or monitored
expectantly. Induction of labour might prevent maternal complications. However, induction of labour in late pre-
term pregnancy might increase neonatal morbidity and mortality compared with delivery at term.
Methods/Design: Pregnant women with severe gestational hypertension, mild pre-eclampsia or deteriorating
chronic hypertension at a gestational age between 34+0 and 36+6 weeks will be asked to participate in a multi-
centre randomised controlled trial. Women will be randomised to either induction of labour or expectant
monitoring. In the expectant monitoring arm, women will be induced only when the maternal or fetal condition
detoriates or at 37+0 weeks of gestation. The primary outcome measure is a composite endpoint of maternal
mortality, severe maternal complications (eclampsia, HELLP syndrome, pulmonary oedema and thromboembolic
disease) and progression to severe pre-eclampsia. Secondary outcomes measures are respiratory distress syndrome
(RDS), neonatal morbidity and mortality, caesarean section and vaginal instrumental delivery rates, maternal quality
of life and costs. Analysis will be intention to treat. The power calculation is based on an expectant reduction of
the maternal composite endpoint from 5% to 1% for an expected increase in neonatal RDS from 1% at 37 weeks
to 10% at 34 weeks. This implies that 680 women have to be randomised.
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Discussion: This trial will provide insight as to whether in women with hypertensive disorders late pre-term,
induction of labour is an effective treatment to prevent severe maternal complications without compromising the
neonatal morbidity.
Trial Registration: NTR1792 Clinical trial registration: http://www.trialregister.nl
Background
Hypertensive disorders (including gestational hyperten-
sion (GH) and pre-eclampsia (PE)) complicate 10% of all
pregnancies and can result in severe complications for
the mother such as eclampsia, placental abruption, pre-
term delivery, the syndrome of Hemolysis, Elevated
Liver enzymes and Low Platelets (HELLP) and ulti-
mately even neonatal and maternal death [1]. Hyperten-
sive disorders in pregnancy are the largest cause of
maternal mortality in the Netherlands [2,3]. Unfortu-
nately, maternal mortality in the Netherlands has
increased over the past decade, with pre-eclampsia
remaining the number one cause of maternal death [4].
The majority of the cases of GH and PE declare itself
after 32 weeks. As the origins of hypertensive disorders
are probably related to faulty implantation of the pla-
centa early in pregnancy, the only causal treatment of
the disease is immediate delivery. Delivery will result in
removal of the placenta, which will result in disappear-
ance of the signs and symptoms of GH or PE within a
few days. The timing of induction of labour has been
debated, as induction was thought to increase the num-
ber of caesarean sections and in case of pre-term deliv-
ery, might compromise neonatal outcome. Our recent
HYPITAT-I study provided us evidence that in women
with GH and PE above a gestational age of 37 weeks,
induction of labour not only resulted in a decrease of
progression to severe pre-eclampsia or maternal compli-
cations, but unexpected also in a decrease in the num-
ber of caesarean sections (19% versus 14%, RR 0.75, 95%
CI 0.55 - 1.04) [5]. Moreover, induction of labour
showed a trend to a better neonatal outcome, a better
maternal quality of life and a reduction in costs [6,7].
However for women with GH, PE or deteriorating
chronic hypertension in the late pre-term period (e.g.
34, 35 and 36 weeks’ gestation), there remains uncer-
tainty on the best policy. The situation in these patients
is different, as apart from maternal morbidity, the condi-
tion of the child is at state. Late pre-term born children
experience significantly more morbidity, compared to
children born at term. Unfortunately, children born
from mothers with a hypertensive disorder were mostly
excluded from studies [8-10]. Thus, for women with
hypertensive related complications of pregnancy
between 34 and 37 weeks, the issue on whether these
women should be monitored expectantly or not,
remains an obstetric dilemma. In addition, the NICE
guideline “hypertensive disorders during pregnancy”
refers in the consensus statement to the issue of mild or
moderate pre-eclampsia between 34 and 36 weeks of
gestation in terms of a “grey zone” at which the optimal
timing of birth is not clear and more research is neces-
sary for this period [11].
In view of the relatively poor outcome of women with
hypertensive pregnancy complications in The Nether-
lands as compared to abroad and in view of the neonatal
morbidity in case of a late pre-term birth, there is a
need for critical evaluation of the management of hyper-
tensive diseases during pregnancy in the late pre-term
period in the Netherlands.
With lack of good clinical evidence on the subject and
the resulting practice variation, we think that additional
data comparing immediate delivery and expectant moni-
toring in patients with hypertensive disease late pre-
term are urgently needed. We therefore propose a
nationwide randomised clinical trial and an economic
cost analysis as well as quality of life analysis on the
subject. We aim to provide data on the balance between
cost (both financial and in terms of neonatal morbidity)
and effects (prevention of maternal complications).
Methods/design
Aims
The aim of this study is to investigate whether planned
induction of labour compared to expectant monitoring
in women with gestational hypertension, mild pre-
eclampsia or deteriorating chronic hypertension at
gestational age of 34 - 37 weeks of pregnancy, will
reduce maternal morbidity and/or increase neonatal
morbidity. We hypothesize that induction of labour will
reduce maternal morbidity and mortality, but to the
costs of increased neonatal morbidity. The study will
also provide insight on whether induction of labour in
women with GH, PE or deteriorating chronic hyperten-
sion in the late pre-term period will influence the qual-
ity of life and costs compared to expectant monitoring.
Long term follow-up of the neonates and the mothers
will be formulated.
Participant/Eligibility Criteria
Patients 18 years of age or older are eligible if they have
gestational hypertension, mild pre-eclampsia or deterior-
ating chronic hypertension at a gestational age between
34+0 and 36+6 weeks of pregnancy. The diagnosis of GH
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is made in case the diastolic blood pressure is equal to
or above 100 mmHg at two occasions at least six hours
apart in a woman who was normotensive until at least
20 weeks of gestation. The diagnosis of mild PE is made
in case the diastolic blood pressure is above 90 mmHg
at two occasions at least six hours apart in a woman
who was normotensive until at least 20 weeks of gesta-
tion and if proteinuria exists (> 300 mg total protein in
a 24 hour urine collection or > 30 in a spot urine pro-
tein:creatinine ratio). The diagnose of chronic hyperten-
sion is made in case the diastolic blood pressure is
equal to or above 90 mmHg at two occasions at least
six hours apart, diagnosed before 20 weeks of gestation.
Women with chronic hypertension are eligible in case
there is need for additional medication or in case super-
imposed PE is diagnosed between 34+0 and 36+6 weeks’
gestation.
Patients with singleton or multiple pregnancies are eli-
gible, independent of the position of the fetus (i.e.
cephalic or breech). Neither diabetes mellitus, nor small
for gestational age nor a history of caesarean section are
exclusion criteria. Randomisation only occurs after
informed consent.
Exclusion criteria are a diastolic blood pressure equal
to/greater than 110 mmHg despite medication, systolic
blood pressure equal to/greater than 170 mmHg despite
medication, proteinuria equal to/greater than 5 g/L,
eclampsia, HELLP syndrome, pulmonary oedema or cya-
nosis, oliguria less than 500 ml in 24 hours, renal dis-
ease, heart disease, HIV-positive, non-reassuring fetal
heart rate, zero-flow or reverse flow in the umbilical
artery, fetal abnormalities including abnormal karyotype,
severe pre-eclamptic complaints such as frontal head-
ache or ruptured membranes.
Procedures, recruitment, randomisation and collection of
baseline data
Eligible women will be identified by the local research
coordinator and/or the staff of participating hospitals.
After counselling and reading the patient information
form, patients will be asked for written consent. We will
provide patient information in Dutch as well as several
other languages (Turkish, French, Spanish and English),
in order to facilitate inclusion of patients from cultural
minorities. After informed consent, patient data will be
entered in a web-based database, which will also facili-
tate randomisation.
Prior to randomisation, we will perform a digital
examination to establish a Bishop score and we will
measure cervical length. Women will be randomly allo-
cated to either delivery within 24 hours (experimental
arm) or expectant monitoring (control arm) until 37
weeks of gestational age. The study will be an open
label study, as it is impossible to blind the health care
workers and patients involved for the strategy to which
the woman is allocated. Randomisation will be per-
formed centrally with the use of a permuted-block
design, stratified for recruiting centre. Randomisation
will be 1:1 for intervention and expectant monitoring
management. Although it will not be possible to prevent
all cross-overs, both strategies will be performed accord-
ing to strict criteria, as mentioned below.
At study entry baseline demographic, past obstetric
and medical history will be recorded into the web-based
Case Report Form (CRF) that is accessible through a
closed part of a central website. Details of delivery,
maternal and neonatal assessments during pregnancy or
post-partum are recorded in the CRF. The collected
data will be coded and processed with adequate precau-
tions to ensure patient confidentially.
A subset of 200 women will receive quality of life
questionnaires prior to randomisation, one day after
randomisation and subsequently after 1 week, 2 weeks,
6 weeks, 3 months and 6 months. Since the gestational
age at delivery will differ between the two groups, we
will ask the participating women also to complete
questionnaires at 1 day and 2 days after delivery. A
pain scale will be added to those questionnaires. We
hypothesize differences on the emotional and anxiety
scales prior to delivery and differences in physical
scales after delivery (due to differences in instrumental
delivery rates). The questionnaires will contain the
Medical Outcome Study 36-Item Short Form Health
Survey (SF-36), the European Quality of Life 6 dimen-
sions 3 levels (EuroQoL 6D3L) with subsequent gen-
eral health Visual Analogue Scale (VAS), the Hospital
Anxiety and Depression scale (HADS), and the Symp-
tom Check List (SCL-90), all validated in Dutch and
English.
Interventions
Immediately delivery
In the intervention group labour will be induced within
24 hours after randomisation. Induction of labour con-
sists of amniotomy and augmentation of labour by
administration of oxytocine. In case of an unfavourable
cervix induction of labour will be preceded according to
the local protocol. Prostaglandins will not be adminis-
tered to women with a history of caesarean section. Cer-
vical dilatation in these women will be achieved by a
cervical Foley catheter followed by amniotomy and aug-
mentation of labour with oxytocine. In case the patient
gives no consent for vaginal delivery (for example
breech presentation or history of two caesarean sec-
tions) the patient will be delivered by caesarean section
within 24 hours after randomisation. After delivery, all
patients in the intervention group will be monitored
clinically.
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Expectant monitoring until 37 weeks
In the expectant monitoring group, patients will be
monitored until the onset of spontaneous delivery. If
onset of labour has not occurred at 37+0 weeks gesta-
tion, labour will be induced. Monitoring will consist of
assessment of fetal movements as reported by the
mother, as well as electronic fetal heart rate monitoring
at least twice a week. Maternal evaluation consists pri-
marily of frequent evaluation of blood pressure mea-
surement and screening of urine for protein using a
dipstick or protein/creatinin ratio twice a week (24 hour
urine collection for protein in case of positive screen-
ing). Blood tests (platelet count, liver enzymes and renal
function) will be performed in case of abnormal mater-
nal blood pressure and/or proteinuria. In the expectant
monitoring group, intervention is recommended in case
the fetal or maternal condition does not justify expec-
tant monitoring anymore. These criteria are similar to
the exclusion criteria of the trial. All patients in the
expectant monitoring group will be monitored clinically
until after delivery.
Follow-up of women and infants
All details of delivery, maternal and neonatal assess-
ments and admission during pregnancy are recorded in
the CRF that is accessible through the website. Mortality
and morbidity will be specified for the mother and the
child until date of discharge from hospital and six weeks
postpartum.
We plan long term follow-up at the age of 2 years with
the Ages & Stages Questionnaires (ASQ) and the Child
Behavioral Checklist (CBCL). By means of e-mails gener-
ated by our web-based registration system, our research
nurses will be notified when a child approaches the cor-
rected age of two years. After this alert, the research
nurse will approach the parents of the child by phone
and announce the sending of the questionnaire. In case
the parents do not return the questionnaire, a reminder
will be sent. We use the validated Dutch translation of
the ASQ, covering the age-range 4-60 months and the
validated Dutch translation of the CBCL 11/2 - 5 years
[12]. The ASQ is developed as a developmental screener
and has been validated to pick up children at risk of a
developmental disability. The CBCL (Child Behavioral
Checklist) evaluates maladaptive behavioral and emo-
tional problems in children reported by parents. It
assesses internalizing (i.e., anxious, depressive, and over-
controlled) and externalizing (i.e., aggressive, hyperactive,
noncompliant, and undercontrolled) behaviors. We will
compare the total mean scores and T-scores between
study arms and in addition we will compare the number
of children scoring at 2 standard deviations below the
mean of the Dutch reference group. A plan for long term
follow-up of the mothers on their cardiovascular risk in
the future is in preparation [13].
Outcome measures
Primary outcome measure
The primary outcome measure will be a composite end-
point of maternal mortality, maternal complications
(eclampsia, HELLP syndrome, pulmonary oedema, thro-
moembolic disease) and progression to severe pre-
eclampsia. Eclampsia is defined as severe gestational
hypertension or pre-eclampsia resulting in maternal sei-
zures [14]. HELLP syndrome is defined as a complica-
tion of severe pre-eclampsia involving Hemolysis,
Elevated Liver functions, and Low Platelets [14,15].
Thromboembolic disease is defined as deep-vein throm-
bosis, pulmonary embolism or both. Patients will be
examined for deep-vein thrombosis by duplex Doppler
if thrombosis is suspected from clinical examination. A
diagnosis of pulmonary embolism will be confirmed by
pulmonary angiography, computed tomography, mag-
netic resonance imaging or a ventilation-perfusion lung
scan [16-18].
Progression to severe pre-eclampsia is defined as dia-
stolic blood pressure equal/greater than 110 mmHg
despite medication, systolic blood pressure equal/greater
than 170 mmHg despite medication and/or proteinuria
equal to/greater than 5 g/L.
The neonatal primary outcome will be respiratory dis-
tress syndrome (RDS). Diagnosis of RDS requires signs
of respiratory distress, consistent radiologic features, and
oxygen therapy with a fraction of inspired oxygen
(FIO2) of 0.40 or greater for at least 24 hours or until
death [19].
Secondary outcome measures
Secondary maternal outcomes will be caesarean sec-
tion rate, instrumental vaginal delivery rate, maternal
quality of life and costs. Secondary neonatal outcomes
will be transient tachypnoe of the newborn, hypoglycae-
mia, newborn sepsis, confirmed seizures, necrotizing
enterocolitis, hypoxic-ischemic encephalopathy, cardio-
pulmonary resuscitation or ventilator support within 24
hours after birth, umbilical-cord-blood arterial pH
below 7.0, a 5-minute Apgar score of 3 or below, admis-
sion to the neonatal intensive care unit (NICU) or neo-
natal death [19]. Transient tachypnoe of the newborn is
defined by the presence of tachypnoe within hours after
birth and typical radiologic findings. The diagnosis of
necrotizing enterocolitis requires confirmation by radi-
ologic findings, surgery, or autopsy. The diagnosis of
hypoglycaemia requires a serum or plasma glucose level
of less than 35 mg per decilitre (1.9 mmol per litre) and
treatment with intravenous glucose. Newborn sepsis
includes both suspected infections (with clinical findings
suggesting infection) and proved infections (as con-
firmed in a subgroup of neonates with positive cultures
of blood, cerebrospinal fluid, or urine obtained by cathe-
terization or suprapubic aspiration; cardiovascular
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collapse; or an unequivocal radiograph confirming infec-
tion in a neonate with clinical sepsis).
Statistical issues
Data analysis
Data will be analysed on an intention-to-treat basis.
Analysis of data includes comparison of maternal base-
line characteristics at randomisation, maternal morbidity
and mortality until hospital discharge and 6 weeks post-
partum, neonatal morbidity and mortality until hospital
discharge, method of delivery, type of hospital care and
days of maternal and neonatal hospital stay. Differences
between groups with normally distributed data will be
tested using the Student’s t test and for data with a
skewed distribution, a non-parametric Mann-Whitney U
test will be used. Categorical data will be analysed with
c2 statistics. Calculation of the percentages will be
based on the number of valid observations. Treatment
effect will be presented as relative risk (RR) with 95%
CIs, and where appropriate as absolute risk reduction
with 95% CIs and number needed to treat. A p-value of
less than 0.05 indicates statistically significance. To asses
treatment effects between different categories of patients
in the trial we will perform subgroup analysis: per gesta-
tional age of the fetus per week (34+0 - 34+6, 35+0 - 35+6
and 36+0 - 37+0), parity (women with versus women
without a previous vaginal delivery), hypertensive related
disease (gestational hypertension versus pre-eclampsia),
the use of corticosteroids (administered prior to delivery
versus no use), mode of delivery (vaginal delivery versus
caesarean section), caesarean delivery in history (history
of a caesarean delivery versus no history of caesarean
delivery) and the Bishop score (< 2, 2-6 and > 6).
Sample size
We hypothesize that immediate delivery can reduce
maternal complications from 5% to 1%. Using a two
sided test (alpha error 5%, beta error 20%) and assuming
a 10% rate lost to follow-up and protocol violations, we
aim to recruit 680 patients. This sample size is also
large enough to assess whether there will be relevant
differences in the primary neonatal outcome (incidence
of RDS around 10% at 34 weeks versus 1-3% at 37
weeks).
Economic analysis
We plan an economic analysis alongside the clinical
trial. This analysis will be performed from the societal
perspective, meaning that we include both medical and
non-medical costs to examine the economic impact of
both strategies on the whole society.
Within the economic evaluation, we will compare the
costs and effects of immediate delivery and expectant
monitoring. The key question in the economic evalua-
tion is to assess whether the expected increase of cost of
maternal care in case of expectant monitoring will be
higher than the expected increase of cost of neonatal
care in case of immediate delivery.
The process of care is distinguished into three cost
stages (antenatal stage, delivery/childbirth, postnatal
stage) and three cost categories (direct medical costs [all
health care sector costs], direct non-medical costs [costs
outside the health care sector that are affected by health
status or health care] and indirect costs of the pregnant
woman and her partner [costs of sick leave].
For each stage and each cost category, costs are mea-
sured as the volumes of resources used multiplied with
appropriate valuation (cost-per-unit estimates, fees,
national reference prices). Cost volumes in the antenatal
stage consist of admissions of the mother, maternal
monitoring with various laboratory tests and fetal moni-
toring. In this stage, direct non-medical and indirect
costs may be generated if role patterns or household
routines shift. Costs generated during delivery are domi-
nated by the course of childbirth and type of delivery.
Resource utilization in the postnatal stage consist of
maternal and neonatal health care during the hospital
admission (maternal ward, NICU/neonatology admis-
sions), and primary care following discharge. If neonatal
health at discharge is suboptimal, further direct medical,
direct non-medical and indirect costs may occur. Hence,
for these infants, resource use of infants and/or parents
is measured up till the corrected child age of 24 months.
Serious adverse events
Serious adverse events will be reported to an indepen-
dent data safety monitoring committee. A formal
interim analysis is not planned.
Ethical consideration
This study has been approved by the ethics committee
of the Academic medical centre Amsterdam (ref.no
MEC 08/244)
Confidentially and data security
Initials of participants as well as a local patient number
are recorded in the electronic database. Linking names
with patients’ numbers can only be done in the local
clinics. Each participating clinic receives a login name
and password to gain access to the web-secured data-
base. The access is restricted to the database of the
clinic to which the password and login name belongs.
Full access to the entire database is restricted to some
members of the research staff.
Discussion
Gestational hypertension (including chronic hyperten-
sion) and pre-eclampsia are important hypertensive dis-
orders during pregnancy which are associated with
increased maternal and neonatal morbidity and mortal-
ity. There is no consensus on how to manage these
hypertensive disorders between 34 and 37 weeks ‘gesta-
tion. Induction of labour will prevent maternal
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complications, but might also increase the neonatal
morbidity due to the pre-term birth.
This trial will provide evidence as to whether or not
induction of labour in women with a hypertensive disor-
der in the late pre-term period is an effective treatment
to prevent severe maternal complication, without com-
promising the neonatal morbidity.
List of abbreviations used
PE: pre-eclampsia; GH: gestational hypertension; HELLP: Hemolysis, Elevated
Liver enzymes and Low Platelets; CRF: Case Report Form; RDS: Respiratory
Distress Syndrome.
Acknowledgements and funding
We thank the collaborators of the study group (gynecologists of the
participating centres for their help as local investigators for the HYPITAT-II
trial); Martijn A. Oudijk, Kitty W. Bloemenkamp, Christianne J. de Groot, Erik
van Beek, Marloes E. van Huizen, Herman P. Oosterbaan, Christine Willekes,
Ella J. Wijnen-Duvekot, Maureen T.M. Franssen, Denise A.M. Perquin, Jan M.J.
Sporken, Mallory D. Woiski, Henk A. Bremer, Dimitri N.M. Papatsonis, Jozien T.
J. Brons, Mesrure Kaplan, Bas W.A. Nij Bijvanck.
This trial is funded by Zon-MW grant (number: 171102012)
Author details
1Department of Obstetrics and Gynecology, Maastricht University Medical
Centre. GROW - School for Oncology and Developmental Biology, The
Netherlands. 2Department of Obstetrics and Gynecology, Martini hospital,
Groningen, The Netherlands. 3Department of Obstetrics and Gynecology,
Academic Medical Centre, Amsterdam, The Netherlands. 4Department of
Obstetrics and Gynecology, Onze Lieve Vrouwe Gasthuis Amsterdam.
5Department of Neonatology, Emma Children’s Hospital, Academic Medical
Centre, Amsterdam, The Netherlands. 6Department of Epidemiology,
University Medical Centre Groningen, The Netherlands. 7Department of
Obstetrics and Gynecology, Maxima Medical Centre, Veldhoven, The
Netherlands. 8Department of Obstetrics and Gynecology, University Medical
Centre Utrecht, The Netherlands. 9Department of Obstetrics and Gynecology,
Leiden University Medical Centre, The Netherlands. 10Department of
Obstetrics and Gynecology, VU Medical Centre Amsterdam, The Netherlands.
11Department of Obstetrics and Gynecology, St. Antonius Hospital
Nieuwegein, The Netherlands. 12Department of Obstetrics and Gynecology,
Haga Hospital Den Haag, The Netherlands. 13Department of Obstetrics and
Gynecology, Jeroen Bosch Hospital, s’-Hertogenbosch, The Netherlands.
14Department of Obstetrics and Gynecology, VieCuri Medical Centre, Venlo,
The Netherlands. 15Department of Obstetrics and Gynecology, Medical
Centre Leeuwarden, Leeuwarden, The Netherlands. 16Department of
Obstetrics and Gynecology, Canisius-Wilhelmina Hospital, Nijmegen, The
Netherlands. 17Department of Obstetrics and Gynecology, Radboud
Univeristy Nijmegen, Nijmegen, The Netherlands. 18Department of Obstetrics
and Gynecology, Reinier de Graaf Hospital, Delft, The Netherlands.
19Department of Obstetrics and Gynecology, Amphia Hospital Breda, The
Netherlands. 20Department of Obstetrics and Gynecology, Medical Spectrum
Enschede, The Netherlands. 21Department of Obstetrics and Gynecology,
Saxenburgh Group, Hardenberg, The Netherlands. 22Department of
Obstetrics and Gynecology, Isala Hospital, Zwolle, The Netherlands.
Authors’ contributions
MP, MvP, BWM and JL were involved in conception and design of the study.
MP, BWM and JL drafted the manuscript. All authors mentioned in the
manuscript are member of the HYPITAT-II study group or collaborators. They
participated in the design of the study during several meetings and are local
investigators at the participating centres. All authors edited the manuscript
and read and approved the final draft.
Competing interests
The authors declare that they have no competing interests.
Received: 12 May 2011 Accepted: 7 July 2011 Published: 7 July 2011
References
1. Sibai BM, Caritis SN, Thom E: Prevention of preeclampsia with low-dose
aspirin in healthy, nulliparous pregnant women. The National Institute
of Child Health and Human Development Network of Maternal-Fetal
Medicine Units. N Engl J Med 1993, 329:1213-8.
2. Schuitemaker NWE, Van Roosmalen J, Dekker GA, et al: Confidential
enquiry into maternal deaths in The Netherlands 1983-1992. Eur J Obstet
Gynecol 1998, 79:57-62.
3. Schuitemaker N, Briet JW, van Roosmalen J, et al: Substandard care bij
moedersterfte. Ned Tijdschrift Obstetr Gynaecol 2001, 114:77-8.
4. Schutte JM, Steegers EA, Schuitemaker NW, Santema JG, de Boer K, Pel M,
Vermeulen G, Visser W, van Roosmalen J, Netherlands Maternal Mortality
Committee: Rise in maternal mortality in the Netherlands. BJOG 2010,
117(4):399-406.
5. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ,
van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW,
Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A,
Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Willekes C,
Mol BW, van Pampus MG, HYPITAT studygroup: Induction of labour versus
expectant monitoring for gestational hypertension or mild pre-
eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label
randomised controlled trial. Lancet 2009, 374(9694):979-88.
6. Vijgen SM, Koopmans CM, Opmeer BC, Groen H, Bijlenga D, Aarnoudse JG,
Bekedam DJ, van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW,
Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A,
Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Stigter RH,
Willekes C, Mol BW, Van Pampus MG, HYPITAT study group: An economic
analysis of induction of labour and expectant monitoring in women
with gestational hypertension or pre-eclampsia at term (HYPITAT trial).
BJOG 2010, 117(13):1577-85.
7. Bijlenga D, Koopmans CM, Birnie E, Mol BWJ, van der Post JA,
Bloemenkamp KW, Scheepers HC, Willekes C, Kwee A, Heres MH, van
Beek E, van Meir CA, van Huizen ME, van Pampus MG, Bonsel GJ: Health-
related quality of life after induction of labour versus expectant
monitoring in gestational hypertension or pre-eclampsia at term.
Hypertens Preg .
8. McIntire DD, Leveno KJ: Neonatal mortality and morbidity rates in late
preterm births compared with births at term. Obstet Gynaecol 2008,
111:35-41.
9. Bird TM, Bronstein JM, Hall RW, Lowery CL, Nugent R, Mays GP: Late
preterm infants: birth outcomes and health care utilization in the first
year. Pediatrics 2010, 126(2):e311-9.
10. Consortium on Safe Labor, Hibbard JU, Wilkins I, Sun L, Gregory K,
Haberman S, Hoffman M, Kominiarek MA, Reddy U, Bailit J, Branch DW,
Burkman R, Gonzalez Quintero VH, Hatjis CG, Landy H, Ramirez M,
VanVeldhuisen P, Troendle J, Zhang J: Respiratory morbidity in late
preterm births. JAMA 2010, 304(4):419-25.
11. NICE guidelines: Hypertension in pregnancy: the management of
hypertensive disorders during pregnancy. 2010 [http://www.nice.org.uk].
12. Kerstjens JM, Bos AF, ten Vergert EMJ, de Meer G, Butcher PR,
Reijneveld SA: Support for global feasibility of the Ages and Stages
Questionnaire as developmental screener. Early Hum Develop 2009,
85:443-447.
13. Hermes W, Franx A, van Pampus MG, Bloemenkamp KW, van der Post JA,
Porath M, Ponjee G, Tamsma JT, Mol BW, de Groot CJ: 10-Year
cardiovascular event risks for women who experienced hypertensive
disorders in late pregnancy: the HyRAS study. BMC Pregnancy Childbirth
2010, 10:28.
14. Sibai BM: Diagnoses, prevention and management of eclampsia. Obstet
Gynecol 2005, 105:402-410.
15. Coppage KH, Sibai BM: Treatment of hypertensive complications in
pregnancy. Curr Phar des 2005, 11:749-757.
16. Barbour LA, ACOG Committee on practice Bulletins obstetrics: ACOG
practice bulletin. Thromboembolism in pregnancy. Int J Gynaecol Obstet
2001, 75:203-12.
17. Danilenko-Dixon DR, Heit JA, Silverstein MD, Yawn BP, Petterson TM,
Lohse CM, Melton LJ: Risk factors for deep vein thrombosis and
pulmonary embolism during pregnancy or post partum: a population-
based, case-control study. Am J Obstet Gynecol 2001, 184:104-10.
18. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ:
Trends in the incidence of venous thromboembolism during pregnancy
Langenveld et al. BMC Pregnancy and Childbirth 2011, 11:50
http://www.biomedcentral.com/1471-2393/11/50
Page 6 of 7
or postpartum: a 30-year population-based study. Ann Intern Med 2005,
143:697-706.
19. Tita AT, et al: Timing of elective repeat cesarean delivery at term and
neonatal outcomes. N Engl J Med 2009, 360:111-20.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2393/11/50/prepub
doi:10.1186/1471-2393-11-50
Cite this article as: Langenveld et al.: Induction of labour versus
expectant monitoring for gestational hypertension or mild pre-
eclampsia between 34 and 37 weeks’ gestation (HYPITAT-II): a
multicentre, open-label randomised controlled trial. BMC Pregnancy and
Childbirth 2011 11:50.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Langenveld et al. BMC Pregnancy and Childbirth 2011, 11:50
http://www.biomedcentral.com/1471-2393/11/50
Page 7 of 7
